NICE advises on sunitinib in renal cell carcinoma

NICE has issued criteria that should be met before the use of sunitinib should be considered.

The guidance states that sunitinib may be used as first-line therapy in people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

The guidance also states that people who are currently being treated with sunitinib for advanced and/or metastatic renal cell carcinoma but who do not meet these criteria should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

A summary of the new guidance is available at www.mims.co.uk. To read the full guidance visit the NICE website.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more